Oriented carbon nanostructures grown by hot-filaments plasma-enhanced CVD from self-assembled Co-based catalyst on Si substrates

International audienc

Titanium dioxide nanoparticles prepared by laser pyrolysis : synthesis and photocatalytic properties

TiO2 nanoparticles were synthesized via the laser pyrolysis of titanium tetrachloride-based gas-phase mixtures. In the obtained nanopowders, a mixture of anatase and rutile phases with mean particle size of about 14 nm was identified. Using the thermal heated laser nanopowders, mechanically stable films were produced by immobilizing titania nanopowders on glass substrates (the doctor blading method followed by compression). The photocatalytic activity of the prepared films was tested by the degradation of 4-chlorophenol in an aqueous solution under UV-illumination. By referring to known commercial samples (Degussa P25) similarly prepared, higher photocatalytic efficiency was found for the laser-prepared samples

Carbon nanotubes growth from C2H2 and C2H4/NH3 by catalytic LCVD on supported iron-carbon nanocomposites

We report about the synthesis of carbon nanotubes by catalytic LCVD (C-LCVD), using a CW CO2 laser and alternatively, C2H2/ C2H4/NH3 and C2H2/C2H4-containing gas mixtures. Different core-shell Fe-C nanocomposites (as synthesized and toluene extracted) were used employed as catalysts. The nanotubes grown from Fe-C residue demonstrate the lowest mean diameters. Prevalent curled and coiled morphologies are obtained for the CNTs grown in the presence of ammonia. (c) 2006 Elsevier B.V. All rights reserved

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events